View Future GrowthPacific Edge 過去の業績過去 基準チェック /06Pacific Edgeの収益は年間平均-16.6%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間33.8% 19.6%割合で 増加しています。主要情報-16.63%収益成長率-13.55%EPS成長率Biotechs 業界の成長17.04%収益成長率19.55%株主資本利益率-128.45%ネット・マージン-189.40%次回の業績アップデート24 May 2026最近の業績更新お知らせ • May 12Pacific Edge Limited to Report Fiscal Year 2026 Results on May 25, 2026Pacific Edge Limited announced that they will report fiscal year 2026 results at 10:00 AM, IDLE - International Date Line on May 25, 2026お知らせ • Nov 06Pacific Edge Limited to Report First Half, 2026 Results on Nov 25, 2025Pacific Edge Limited announced that they will report first half, 2026 results on Nov 25, 2025お知らせ • May 12Pacific Edge Limited to Report Fiscal Year 2025 Results on May 30, 2025Pacific Edge Limited announced that they will report fiscal year 2025 results at 4:45 PM, IDLE - International Date Line on May 30, 2025お知らせ • Nov 06Pacific Edge Limited to Report First Half, 2025 Results on Nov 26, 2024Pacific Edge Limited announced that they will report first half, 2025 results on Nov 26, 2024お知らせ • May 01Pacific Edge Limited to Report Fiscal Year 2024 Results on May 21, 2024Pacific Edge Limited announced that they will report fiscal year 2024 results at 10:00 AM, NZST - New Zealand Standard on May 21, 2024お知らせ • Oct 19Pacific Edge Limited to Report First Half, 2024 Results on Nov 23, 2023Pacific Edge Limited announced that they will report first half, 2024 results on Nov 23, 2023すべての更新を表示Recent updatesお知らせ • May 15Pacific Edge Limited has completed a Follow-on Equity Offering in the amount of NZD 25.4 million.Pacific Edge Limited has completed a Follow-on Equity Offering in the amount of NZD 25.4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 149,411,765 Price\Range: NZD 0.17 Transaction Features: Subsequent Direct Listingお知らせ • May 12Pacific Edge Limited to Report Fiscal Year 2026 Results on May 25, 2026Pacific Edge Limited announced that they will report fiscal year 2026 results at 10:00 AM, IDLE - International Date Line on May 25, 2026お知らせ • Nov 06Pacific Edge Limited to Report First Half, 2026 Results on Nov 25, 2025Pacific Edge Limited announced that they will report first half, 2026 results on Nov 25, 2025お知らせ • Jun 16Pacific Edge Limited, Annual General Meeting, Aug 06, 2025Pacific Edge Limited, Annual General Meeting, Aug 06, 2025. Location: auckland New Zealandお知らせ • Jun 03Pacific Edge Limited has completed a Follow-on Equity Offering in the amount of NZD 16 million.Pacific Edge Limited has completed a Follow-on Equity Offering in the amount of NZD 16 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 150,000,000 Price\Range: NZD 0.1 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,000,000 Price\Range: NZD 0.1 Transaction Features: Subsequent Direct Listingお知らせ • May 31Pacific Edge Limited has filed a Follow-on Equity Offering in the amount of NZD 5 million.Pacific Edge Limited has filed a Follow-on Equity Offering in the amount of NZD 5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 50,000,000 Price\Range: NZD 0.1お知らせ • May 30Pacific Edge Limited has filed a Follow-on Equity Offering.Pacific Edge Limited has filed a Follow-on Equity Offering. Security Name: Ordinary Shares Security Type: Common Stock Transaction Features: Subsequent Direct Listingお知らせ • May 12Pacific Edge Limited to Report Fiscal Year 2025 Results on May 30, 2025Pacific Edge Limited announced that they will report fiscal year 2025 results at 4:45 PM, IDLE - International Date Line on May 30, 2025お知らせ • Nov 06Pacific Edge Limited to Report First Half, 2025 Results on Nov 26, 2024Pacific Edge Limited announced that they will report first half, 2025 results on Nov 26, 2024お知らせ • May 07Pacific Edge Limited, Annual General Meeting, Sep 24, 2024Pacific Edge Limited, Annual General Meeting, Sep 24, 2024.お知らせ • May 01Pacific Edge Limited to Report Fiscal Year 2024 Results on May 21, 2024Pacific Edge Limited announced that they will report fiscal year 2024 results at 10:00 AM, NZST - New Zealand Standard on May 21, 2024お知らせ • Mar 14Pacific Edge Limited Announces Board ChangesPacific Edge Limited announced the retirement of Chair Chris Gallaher and Non-Executive Director Mark Green. Mr. Gallaher, who joined the Pacific Edge Board in July 2016, has resolved to reduce his governance commitments, and has indicated his intention to retire from the Board following the appointment of a successor and a structured handover at the end of this year. Meanwhile, with his family having made new commitments offshore, Mr. Green has notified the Board he does not intend to seek re-election at the company's next Annual Shareholders Meeting in September. Mr. Green joined the Pacific Edge Board in May 2021. The Board's Nomination Committee has commenced a process to appoint a new Chair and consider the recruitment of new Independent Directors.お知らせ • Oct 19Pacific Edge Limited to Report First Half, 2024 Results on Nov 23, 2023Pacific Edge Limited announced that they will report first half, 2024 results on Nov 23, 2023お知らせ • Jun 09Pacific Edge Limited Announces Medicare Coverage of Cxbladder Tests in the US Market is Expected to Cease from 17 July 2023Pacific Edge announces Medicare coverage of Cxbladder tests in the US market is expected to cease from 17 July 2023. This development follows the finalization of a Local Coverage Determination (LCD) (L39365) by Novitas, the Medicare Administrative Contractor (MAC) with jurisdiction for Pacific Edge's laboratory in Hershey Pennsylvania. The finalized LCD, which includes Cxbladder and tests provided by other companies, specifically notes the Cxbladder tests Triage, Detect, Monitor, Resolve and Detect+ as `not considered medically reasonable and necessary', the threshold required for coverage under the US Social Security Act. A number of other companies are also affected by the LCD. Over the coming days Pacific Edge will seek to explore all available legal options (including a potential appeal) with US-based lawyers, the key opinion leaders among customers, partners at The Coalition for 21st Century Medicine, and other impacted companies. Pacific Edge is currently unable to fully determine the impact of the new LCD on test volumes in the US market for the 2024 financial year. For the immediate future, the company will continue to promote Cxbladder and process all tests ordered by US clinicians whilst it further considers its strategy and future options. The company believes that in the short term it is prudent to continue to support Cxbladder as it determines the best path forward, but the approach will be accompanied by cost containment initiatives including, but not limited to an immediate hiring freeze and a halt on discretionary spending and new capital expenditure. In light of this new LCD, management and the Board at Pacific Edge are reviewing the scenario planning commenced last year to determine a strategic path forward that potentially includes: a) legal challenges or appeals, b) seeking to regain coverage through Novitas, c) seeking to be awarded coverage through an alternative MAC, d) alternative billing practices that would increase patient responsibility and e) remaining open to other strategic alternatives. Which of these the company adopts, will be determined by considering a number of factors including the potential impact on revenue, expenditure and cash reserves, the time and resources required to regain coverage, shareholder value implications, and the expected likelihood of success.New Risk • Jun 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$53.3m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (NZ$3.9m net loss in 3 years). Market cap is less than US$100m (US$53.3m market cap).収支内訳Pacific Edge の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:PFGT.F 収益、費用、利益 ( )NZD Millions日付収益収益G+A経費研究開発費30 Sep 2518-35271430 Jun 2520-32271531 Mar 2523-30271531 Dec 2423-29281430 Sep 2423-29281430 Jun 2424-29321331 Mar 2425-30351231 Dec 2325-31371130 Sep 2326-32391030 Jun 2323-2937931 Mar 2321-2735831 Dec 2219-2432730 Sep 2216-2128630 Jun 2215-2125631 Mar 2213-2022531 Dec 2112-1820530 Sep 2112-1618530 Jun 2110-1517531 Mar 219-1415531 Dec 207-1514430 Sep 206-1714430 Jun 205-1814431 Mar 205-1915431 Dec 195-1915530 Sep 195-1915630 Jun 195-1815531 Mar 195-1815431 Dec 185-1815230 Sep 185-1815030 Jun 185-1915031 Mar 185-2016031 Dec 174-2018030 Sep 173-2120030 Jun 174-2217031 Mar 174-2314031 Dec 166-219030 Sep 168-204030 Jun 167-184031 Mar 166-163031 Dec 155-153030 Sep 154-153030 Jun 154-1430質の高い収益: PFGT.Fは現在利益が出ていません。利益率の向上: PFGT.Fは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: PFGT.Fは利益が出ておらず、過去 5 年間で損失は年間16.6%の割合で増加しています。成長の加速: PFGT.Fの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: PFGT.Fは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 43% ) と比較することは困難です。株主資本利益率高いROE: PFGT.Fは現在利益が出ていないため、自己資本利益率 ( -128.45% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 01:45終値2026/05/15 00:00収益2025/09/30年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Pacific Edge Limited 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関null nullBrookline Capital MarketsMaxim JacobsEdison Investment ResearchMatt MontgomerieForsyth Barr Group Ltd.4 その他のアナリストを表示
お知らせ • May 12Pacific Edge Limited to Report Fiscal Year 2026 Results on May 25, 2026Pacific Edge Limited announced that they will report fiscal year 2026 results at 10:00 AM, IDLE - International Date Line on May 25, 2026
お知らせ • Nov 06Pacific Edge Limited to Report First Half, 2026 Results on Nov 25, 2025Pacific Edge Limited announced that they will report first half, 2026 results on Nov 25, 2025
お知らせ • May 12Pacific Edge Limited to Report Fiscal Year 2025 Results on May 30, 2025Pacific Edge Limited announced that they will report fiscal year 2025 results at 4:45 PM, IDLE - International Date Line on May 30, 2025
お知らせ • Nov 06Pacific Edge Limited to Report First Half, 2025 Results on Nov 26, 2024Pacific Edge Limited announced that they will report first half, 2025 results on Nov 26, 2024
お知らせ • May 01Pacific Edge Limited to Report Fiscal Year 2024 Results on May 21, 2024Pacific Edge Limited announced that they will report fiscal year 2024 results at 10:00 AM, NZST - New Zealand Standard on May 21, 2024
お知らせ • Oct 19Pacific Edge Limited to Report First Half, 2024 Results on Nov 23, 2023Pacific Edge Limited announced that they will report first half, 2024 results on Nov 23, 2023
お知らせ • May 15Pacific Edge Limited has completed a Follow-on Equity Offering in the amount of NZD 25.4 million.Pacific Edge Limited has completed a Follow-on Equity Offering in the amount of NZD 25.4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 149,411,765 Price\Range: NZD 0.17 Transaction Features: Subsequent Direct Listing
お知らせ • May 12Pacific Edge Limited to Report Fiscal Year 2026 Results on May 25, 2026Pacific Edge Limited announced that they will report fiscal year 2026 results at 10:00 AM, IDLE - International Date Line on May 25, 2026
お知らせ • Nov 06Pacific Edge Limited to Report First Half, 2026 Results on Nov 25, 2025Pacific Edge Limited announced that they will report first half, 2026 results on Nov 25, 2025
お知らせ • Jun 16Pacific Edge Limited, Annual General Meeting, Aug 06, 2025Pacific Edge Limited, Annual General Meeting, Aug 06, 2025. Location: auckland New Zealand
お知らせ • Jun 03Pacific Edge Limited has completed a Follow-on Equity Offering in the amount of NZD 16 million.Pacific Edge Limited has completed a Follow-on Equity Offering in the amount of NZD 16 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 150,000,000 Price\Range: NZD 0.1 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,000,000 Price\Range: NZD 0.1 Transaction Features: Subsequent Direct Listing
お知らせ • May 31Pacific Edge Limited has filed a Follow-on Equity Offering in the amount of NZD 5 million.Pacific Edge Limited has filed a Follow-on Equity Offering in the amount of NZD 5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 50,000,000 Price\Range: NZD 0.1
お知らせ • May 30Pacific Edge Limited has filed a Follow-on Equity Offering.Pacific Edge Limited has filed a Follow-on Equity Offering. Security Name: Ordinary Shares Security Type: Common Stock Transaction Features: Subsequent Direct Listing
お知らせ • May 12Pacific Edge Limited to Report Fiscal Year 2025 Results on May 30, 2025Pacific Edge Limited announced that they will report fiscal year 2025 results at 4:45 PM, IDLE - International Date Line on May 30, 2025
お知らせ • Nov 06Pacific Edge Limited to Report First Half, 2025 Results on Nov 26, 2024Pacific Edge Limited announced that they will report first half, 2025 results on Nov 26, 2024
お知らせ • May 07Pacific Edge Limited, Annual General Meeting, Sep 24, 2024Pacific Edge Limited, Annual General Meeting, Sep 24, 2024.
お知らせ • May 01Pacific Edge Limited to Report Fiscal Year 2024 Results on May 21, 2024Pacific Edge Limited announced that they will report fiscal year 2024 results at 10:00 AM, NZST - New Zealand Standard on May 21, 2024
お知らせ • Mar 14Pacific Edge Limited Announces Board ChangesPacific Edge Limited announced the retirement of Chair Chris Gallaher and Non-Executive Director Mark Green. Mr. Gallaher, who joined the Pacific Edge Board in July 2016, has resolved to reduce his governance commitments, and has indicated his intention to retire from the Board following the appointment of a successor and a structured handover at the end of this year. Meanwhile, with his family having made new commitments offshore, Mr. Green has notified the Board he does not intend to seek re-election at the company's next Annual Shareholders Meeting in September. Mr. Green joined the Pacific Edge Board in May 2021. The Board's Nomination Committee has commenced a process to appoint a new Chair and consider the recruitment of new Independent Directors.
お知らせ • Oct 19Pacific Edge Limited to Report First Half, 2024 Results on Nov 23, 2023Pacific Edge Limited announced that they will report first half, 2024 results on Nov 23, 2023
お知らせ • Jun 09Pacific Edge Limited Announces Medicare Coverage of Cxbladder Tests in the US Market is Expected to Cease from 17 July 2023Pacific Edge announces Medicare coverage of Cxbladder tests in the US market is expected to cease from 17 July 2023. This development follows the finalization of a Local Coverage Determination (LCD) (L39365) by Novitas, the Medicare Administrative Contractor (MAC) with jurisdiction for Pacific Edge's laboratory in Hershey Pennsylvania. The finalized LCD, which includes Cxbladder and tests provided by other companies, specifically notes the Cxbladder tests Triage, Detect, Monitor, Resolve and Detect+ as `not considered medically reasonable and necessary', the threshold required for coverage under the US Social Security Act. A number of other companies are also affected by the LCD. Over the coming days Pacific Edge will seek to explore all available legal options (including a potential appeal) with US-based lawyers, the key opinion leaders among customers, partners at The Coalition for 21st Century Medicine, and other impacted companies. Pacific Edge is currently unable to fully determine the impact of the new LCD on test volumes in the US market for the 2024 financial year. For the immediate future, the company will continue to promote Cxbladder and process all tests ordered by US clinicians whilst it further considers its strategy and future options. The company believes that in the short term it is prudent to continue to support Cxbladder as it determines the best path forward, but the approach will be accompanied by cost containment initiatives including, but not limited to an immediate hiring freeze and a halt on discretionary spending and new capital expenditure. In light of this new LCD, management and the Board at Pacific Edge are reviewing the scenario planning commenced last year to determine a strategic path forward that potentially includes: a) legal challenges or appeals, b) seeking to regain coverage through Novitas, c) seeking to be awarded coverage through an alternative MAC, d) alternative billing practices that would increase patient responsibility and e) remaining open to other strategic alternatives. Which of these the company adopts, will be determined by considering a number of factors including the potential impact on revenue, expenditure and cash reserves, the time and resources required to regain coverage, shareholder value implications, and the expected likelihood of success.
New Risk • Jun 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$53.3m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (NZ$3.9m net loss in 3 years). Market cap is less than US$100m (US$53.3m market cap).